Benzinga · Sep 16, 2026
Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001737953/000110465926108243/tm2625488d1_8k.htm
RE
NASDAQ · REPL
Replimune Group, Inc.
Healthcare · Biotechnology
$13.45
Down-$0.55 (-4.05%)
Updated Oct 2, 2026, 5:22 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 774.6M
- P/E ratio
- -3.23
- Dividend yield
- 0.00%
- 52-week range
- $1.50 – $16.33
- Volume
- 2.52M
- Avg. volume
- 5.08M
Price performance · REPL
REPL price history
1M range · 0 trading sessions · Daily adjusted prices
REPL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest REPL news
The latest Smart Investors Daily articles mentioning REPL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
REPL research
Overview
Company profile and research snapshot.
Company profile
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Wedbush | Outperform | — |
| Aug 4, 2026 | Leerink Partners | Outperform | — |
| Jul 31, 2026 | Wedbush | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
Replimune Group, Inc. (REPL) Shareholder/Analyst Call September 15, 2026 8:30 AM EDTCompany ParticipantsPhilip Astley-Sparke - Executive ChairmanShawn...
Yahoo · Sep 3, 2026
Replimune to Present at the Cantor Global Healthcare Conference 2026
WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be availa
Benzinga · Aug 26, 2026
JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
